BIO Alabama

Our executive director, Kathy Nugent, Ph.D., has been named Senior Associate Vice President and Chief Biotechnology and Innovation Officer for the University of Alabama at Birmingham. Congratulations to an incredible leader!

We had such an exciting and inspiring gathering last week at the Grand Hotel in Point Clear showcasing South Alabama’s thriving BioTech ecosystem with groundbreaking innovations shaping the future of technology, healthcare, and agriculture. The room was filled with passionate individuals connecting and sharing ideas making progress in the fields of bioscience, biotechnology and innovation. Thank you Hatch Fairhope and to our amazing partners—Coastal Alabama Community College, City Of Fairhope, Baldwin County Economic Development Alliance and Innovate Alabama. Also, a special thanks to our sponsors C2 Wealth Strategies and Collaborative Drug Discovery - CDD Vault for their generous support in making this event possible. #BIOAlabama #HatchFairhope #CACC #CityofFairhope #BaldwinCountyEconomicDevelopmentAlliance #InnovateAlabama #C2WealthStrategies #CollaborativeDrugDiscovery #CDDVault #GrandHotelPointClear #Bioscience #Biotech #bioinnovation

Did you know that Dothan is known as the Peanut Capital of the World? The heart of the Wiregrass thrives because of the hardworking communities that sustain it. Within a 100-mile radius, you'll find the majority of the peanuts grown in the United States—feeding industries, supporting local economies, and carrying on a rich agricultural legacy. From dedicated farmers to innovative researchers, we’re not just growing peanuts—we’re growing opportunities, strengthening communities, and inspiring the next generation of agricultural leaders! 🌱🥜 Happy National Peanut Month! 🥜🌱#NationalPeanutMonth #HudsonAlphaWiregrass #DiscoveringWiregrassDNA

In business news,  IN8bio, Inc., a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies, today unveiled INB-600, its potentially breakthrough next generation γδ T cell-based TCE platform. It is designed to address one of the biggest shortcomings of current existing γδ TCEs – insufficient numbers of γδ T cell effector cells to drive real clinical impact. This groundbreaking platform leverages γδ T cells’ unique properties targeting applications in both oncology and autoimmune indications with potentially greater safety and tolerability than current CAR-T and TCE approaches. The platform’s first candidate, INB-619, targets CD19, a key marker broadly found on B cells, which play a central role in leukemias, lymphomas, and autoimmune diseases. IN8bio plans to evaluate INB-619 in preclinical studies and seek potential partners to support future IND-enabling trials. #mabs https://lnkd.in/eMyhzzKB

Yesterday we presented at the TD Cowen 45th Healthcare Conference. Excited to introduce our latest innovation—the INB-600 platform! Why does this matter? • T cell engagers (TCEs) have been one of the biggest success stories in immunotherapy, with companies like J&J and Roche building billion-dollar franchises around these therapies. • Despite the promise, gamma-delta T cell engagers have struggled—until now. • Our INB-619 preclinical candidate is designed to not only engage γδ T cells but also expand them, creating a more powerful, longer-lasting immune response for blood cancers and autoimmune diseases. • Unlike traditional CD3-based TCEs, which come with severe risks like cytokine release syndrome and neurotoxicity, our approach could offer a safer, more effective alternative. This is a game-changing moment for gamma-delta T cell therapies. Stay tuned for more updates as we continue to work on achieving our goal of #CancerZero!  #Biotech #Immunotherapy #CancerResearch #TcellEngagers #GDTcells

#NEWS: We are pleased to announce new data on our next-generation gamma-delta (γδ) T cell Engager (TCE) platform for oncology and autoimmune diseases – INB-600. INB-600 is a novel γδ T cell-based TCE platform designed to address one of the biggest shortcomings of current existing γδ TCEs – insufficient numbers of γδ T cell effector cells to drive real clinical impact. This technology is designed to efficiently eliminate target cells while stimulating γδ T cell expansion to drive deeper and potentially longer-lasting immune responses. By leveraging our expertise in γδ T cell biology, we have developed a technology that combines exceptional preclinical potency while broadly expanding immune surveillance and potentially avoiding the dangerous side effects of existing approaches. Our CEO, William Ho, will discuss this platform and data today at 10:30 a.m. EST at the TD Cowen 45th Annual Health Care Conference. A webcast will also be available. Read more: bit.ly/3EW6oFB

INAB: IN8bio Continued Survival in INB-100 Trial https://buff.ly/4i1bbnu #smallcaps #biotech

Import Tariffs and Supply Chain Resiliency Webinar Registration: https://lnkd.in/ejKQmi3n Date: 3/19/2025 Time: 11:00 AM - 1:00 PM (CDT)  Join the Alabama International Trade Center, JASA, and Kuehne + Nagel Inc. for a free webinar to discuss the 2025 Import Tariffs and Supply Chain Implications.  Agenda: - 2025 Tariffs - China Tariffs - Steel and Aluminum Tariffs - Supply Chain Implications - Tariff Engineering - Nearshoring  Speakers: Carolyn Turner - Assistant Director Research and Training at Alabama International Trade Center Derek Mckenny - Global Customs Business Development Manager at Kuehne + Nagel Matthew Clark - Director, Trade Consulting Solutions NAM at Kuehne + Nagel #2025tariffs #AITC #JASA #KuehneNagel #Supplychain #BioAlabama #Bioeconomy

THE WEIGHT IS OVER 🧡 Our new resM GLP-1 Postbiotic has officially landed. 🚀 Building on the success of resG prebeet ENERGY Prebiotic and its GLP-1 & digestive benefits, we've added this GLP-1 & metabolic health supplement to our line-up. A blend of chromium, white mulberry, fenugreek, Vitamins D & B12, and our proprietary L. Plantarum Postbiotic - resM (the M stands for Metabolism!) is formulated to: ✔️ Boost GLP-1 (by up to 300% in preclinical studies) ✔️ Support healthy blood sugar levels ✔️ Curb cravings Thank you to Yahoo Finance for covering the launch & helping spread the news. And thanks to the whole team for making this possible. Read more, here: https://lnkd.in/eSRWwuUn C. Vivek Lal, MD, FAAP Stefany N. Brittany Zenner Maria Elena Shahryar Stephenie Samudio Casie Jarman Noah V. Brian Peeters Gregory Bonfilio Michael Bush Andrew O'Connor Scott Bush Nancy Wenger Teodora Thea Nicola MD, PhD, MBA Amit Gaggar Gaurav Mehta Sanjay Singh, Ph.D. #resM #metabolichealth #postbiotic #guthealth #glucosesupport #metabolicsupport #glp1 #glp1supplements

TriAltus Bioscience was founded with a clear mission: to solve one of the biggest challenges in protein purification—achieving ultra-pure, high-activity enzymes in a single step. Our story began when a Scientist at the University of Alabama at Birmingham developed a novel affinity purification system that outperformed traditional multi-step methods. The result? CLīM™ technology, an innovative approach that enables single-step, high-yield purification of even the most challenging proteins. Recognizing its potential, TriAltus was formed to bring this technology to scientists and companies worldwide. Today, we are the only manufacturer of genomic enzymes purified using CLīM™, providing high-purity CRISPR nucleases, polymerases, and other critical tools for cutting-edge research and commercial applications. Interested in learning how CLīM™ can transform your workflows? Let’s talk. 📩 https://bit.ly/3Tiatro https://lnkd.in/etDFtM8C #BiotechInnovation #ProteinPurification #TriAltusTechnology #ScientificBreakthrough